Table 2 Multivariate analysis of predictive factors for AML-free survival and overall survival among lenalidomide-treated patients

From: The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)

Baseline characteristic

AML-free survival

Overall survival

HR (95% CI)

p Value

HR (95% CI)

p Value

Dose reduction (time-varying)

0.44 (0.32‒0.62)

< 0.0001

0.47 (0.33–0.66)

< 0.0001

Total dose in cycles 1–3, per LEN 100 mg increase

0.88 (0.80–0.97)

0.012

0.87 (0.79–0.97)

0.008

RBC transfusion burden, units/8 weeks

1.08 (1.03–1.13)

0.0007

1.07 (1.02–1.12)

0.010

Log platelet count, ×109/l

0.68 (0.47–0.81)

0.0007

0.60 (0.46–0.79)

0.0002

FAB classification (RAEB + CMML vs. RA + RARS)

1.48 (1.02–2.13)

0.037

1.45 (1.00–2.10)

0.052

Age, per year increase

1.04 (1.02–1.05)

< 0.0001

1.04 (1.03–1.06)

< 0.0001

  1. AML acute myeloid leukemia; CI confidence interval; CMML chronic myelomonocytic leukemia; FAB French-American-British; HR hazard ratio; LEN lenalidomide; RA refractory anemia; RAEB RA with excess blasts; RARS RA with ring sideroblasts; RBC red blood cell
Back to article page